AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35818418 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG) capsule
Number of subjects: 110
Study 35818418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 35041776 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 1331
Study 35041776 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based mentor mothers (cMM)
Number of subjects: 1331
Study 35041776 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging and cMM
Number of subjects: 1331
Study 35041776 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 1331
Study 35041776 — intervention group
Group type: EXPERIMENTAL
Intervention: cMM and text messaging
Number of subjects: 1331
Study 33674921 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching and self-management strategy–based electronic program (12 weeks, 20 sessions)
Number of subjects: 54
Study 33674921 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and communications technology (ICT) program
Number of subjects: 54
Study 33674921 — intervention group
Group type: COMPARATOR
Intervention: Health coaching and ICT
Number of subjects: 54
Study 32726041 — intervention group
Group type: EXPERIMENTAL
Intervention: Reyanning Mixture (RYN)
Number of subjects: 144
Study 32726041 — intervention group
Group type: EXPERIMENTAL
Intervention: Reyanning Mixture + Amoxicillin Capsules (RYN+Amoxil)
Number of subjects: 144
Study 32726041 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin Capsules (Amoxil)
Number of subjects: 144
Study 34981352 — intervention group
Group type: EXPERIMENTAL
Intervention: External facilitation intervention including assessment of local barriers/facilitators, formation of a local implementation team, site visit for action planning and training/education, cross-facility quarterly calls, monthly coaching calls, and consultation.
Number of subjects: 35
Study 34981352 — intervention group
Group type: COMPARATOR
Intervention: Matched control facilities (no intervention).
Number of subjects: 35
Study 33347565 — intervention group
Group type: EXPERIMENTAL
Intervention: TU2670 (GnRH antagonist) 20 mg
Number of subjects: 16
Study 33347565 — intervention group
Group type: EXPERIMENTAL
Intervention: TU2670 (GnRH antagonist) 40 mg
Number of subjects: 16
Study 33347565 — intervention group
Group type: EXPERIMENTAL
Intervention: TU2670 (GnRH antagonist) 80 mg
Number of subjects: 16
Study 33347565 — intervention group
Group type: EXPERIMENTAL
Intervention: TU2670 (GnRH antagonist) 160 mg
Number of subjects: 16
Study 33347565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 36123055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trehalose (30 g as part of daily bolus enteral feeding for 12 days)
Number of subjects: 20
Study 36123055 — intervention group
Group type: COMPARATOR
Intervention: Standard isocaloric hospital bolus enteral feeding (control group for 12 days)
Number of subjects: 20
Study 34229607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 130
Study 33069106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) with 2 sessions of a brief-MT workshop
Number of subjects: 213
Study 33069106 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-help booklet only)
Number of subjects: 213
Study 36241968 — intervention group
Group type: EXPERIMENTAL
Intervention: Penehyclidine (0.5 mg)
Number of subjects: 100
Study 36241968 — intervention group
Group type: COMPARATOR
Intervention: TIVA alone (normal saline 5 ml)
Number of subjects: 100
Study 33428924 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 IU of oxytocin
Number of subjects: 63
Study 33428924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 34764182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised liposomal amphotericin-B
Number of subjects: 139
Study 34764182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 34199001 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine 2.5 mcg/kg (D)
Number of subjects: 88
Study 34199001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 mcg/kg and ketamine 1 mg/kg (DK)
Number of subjects: 88
Study 35697637 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5Gy in 5 fractions stereotactic body radiotherapy delivered on the prostate gland.
Number of subjects: 9
Study 33047203 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate restoration with Biodentine
Number of subjects: 54
Study 33047203 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate restoration with TotalFill
Number of subjects: 54
Study 33047203 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate restoration with PCM
Number of subjects: 54
Study 33047203 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed restoration with Biodentine
Number of subjects: 54
Study 33047203 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed restoration with TotalFill
Number of subjects: 54
Study 33047203 — intervention group
Group type: COMPARATOR
Intervention: Delayed restoration with PCM
Number of subjects: 54
Study 32813829 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 215
Study 32813829 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 215
Study 32813829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 215
Study 35598891 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine/ephedrine protocol (Group P/E)
Number of subjects: 268
Study 35598891 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine-only protocol (Group C)
Number of subjects: 268
Study 32870726 — intervention group
Group type: EXPERIMENTAL
Intervention: EMS diagnosis of 'seizure-active'
Number of subjects: 300
Study 32870726 — intervention group
Group type: EXPERIMENTAL
Intervention: EMS diagnosis of 'seizure-active' with benzodiazepine treatment
Number of subjects: 300
Study 32870726 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-seizure related diagnoses
Number of subjects: 300
Study 34291724 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 long‐chain polyunsaturated fatty acids (LCPUFA) supplementation (2.5 grams per day)
Number of subjects: 141
Study 34291724 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 141
Study 33071089 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician in Triage (PIT)
Number of subjects: 900
Study 33071089 — intervention group
Group type: COMPARATOR
Intervention: Traditional Emergency Department (ED)
Number of subjects: 900
Study 36371295 — intervention group
Group type: EXPERIMENTAL
Intervention: Altercentric block building group (visuospatial perspective-taking)
Number of subjects: 216
Study 36371295 — intervention group
Group type: COMPARATOR
Intervention: Egocentric block building group (no visuospatial perspective-taking)
Number of subjects: 216
Study 36371295 — intervention group
Group type: EXPERIMENTAL
Intervention: Socialized altercentric block building (visuospatial perspective-taking and verbal interaction)
Number of subjects: 216
Study 36371295 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel altercentric block building (visuospatial perspective-taking only)
Number of subjects: 216
Study 36371295 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired dialogic reading (verbal interaction only)
Number of subjects: 216
Study 32444402 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Characteristics index (HRCi) with clinical parameters
Number of subjects: 577
Study 32444402 — intervention group
Group type: COMPARATOR
Intervention: Control arm (clinicians blinded to HRCi scores)
Number of subjects: 577
Study 32740328 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure at the Baihui (GV20), Fengchi (GB20), Neiguan (PC6), and Shenmen (HT7) points over a 12-week period
Number of subjects: 0
Study 32740328 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education
Number of subjects: 0
Study 34617068 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for drug-susceptible pulmonary tuberculosis
Number of subjects: 124
Study 36367709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (60 mg)
Number of subjects: 21162
Study 36367709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21162
Study 33945964 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-axial ankle muscle training program (passive stretching, control of ankle muscles, active-resistive strengthening using visual feedback for 40 min per day, 5 times per week for 4 weeks)
Number of subjects: 25
Study 33945964 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-axial ankle muscle training program
Number of subjects: 25
Study 33945964 — intervention group
Group type: COMPARATOR
Intervention: Ankle-related physical therapy (control group)
Number of subjects: 25
Study 33880959 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone added to 30 mL of 0.5% ropivacaine
Number of subjects: 79
Study 33880959 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg dexamethasone added to 30 mL of 0.5% ropivacaine
Number of subjects: 79
Study 33880959 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone added to 30 mL of 0.5% ropivacaine
Number of subjects: 79
Study 33880959 — intervention group
Group type: COMPARATOR
Intervention: 0 mg dexamethasone (control group)
Number of subjects: 79
Study 33580533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime cannabis use
Number of subjects: 184765
Study 33580533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use disorder
Number of subjects: 184765
Study 33523029 — intervention group
Group type: EXPERIMENTAL
Intervention: Imposed Intensity (II) aerobic exercise (cycle ergometer, 25 min, 50rpm) at 60-80% maximum heart rate
Number of subjects: 20
Study 33523029 — intervention group
Group type: COMPARATOR
Intervention: Self-Selected Intensity (SSI) aerobic exercise (cycle ergometer, 25 min, 50rpm)
Number of subjects: 20
Study 33523029 — intervention group
Group type: EXPERIMENTAL
Intervention: Imposed Intensity (II) aerobic exercise
Number of subjects: 20
Study 34629104 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-based physical therapy
Number of subjects: 36
Study 34629104 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Standard Physical Therapy)
Number of subjects: 36
Study 33176725 — intervention group
Group type: EXPERIMENTAL
Intervention: Seribantumab (MM-121) added to standard therapy
Number of subjects: 125
Study 33176725 — intervention group
Group type: EXPERIMENTAL
Intervention: HRG positivity testing
Number of subjects: 125
Study 32536440 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart K.448 music
Number of subjects: 32
Study 32536440 — intervention group
Group type: COMPARATOR
Intervention: Quiet environment (control)
Number of subjects: 32
Study 35612971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg/day plus Pembrolizumab 200 mg every 3 weeks (up to 35 cycles)
Number of subjects: 104
Study 35612971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 104
Study 35612971 — intervention group
Group type: COMPARATOR
Intervention: Treatment of Physician's Choice (TPC) - intravenous doxorubicin 60 mg/m2 every 3 weeks or paclitaxel 80 mg/m2 weekly (3 weeks on/1 week off)
Number of subjects: 104
Study 33884702 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 100 mcg
Number of subjects: 25
Study 33884702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 25
Study 33293818 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis with carotid artery calcifications (CAC) (n=16)
Number of subjects: 280
Study 35205636 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Number of subjects: 240
Study 35205636 — intervention group
Group type: COMPARATOR
Intervention: Blue dye
Number of subjects: 240
Study 34603045 — intervention group
Group type: EXPERIMENTAL
Intervention: TRC150094 50 mg
Number of subjects: 46
Study 34603045 — intervention group
Group type: EXPERIMENTAL
Intervention: TRC150094 150 mg
Number of subjects: 46
Study 34524044 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-rounding model
Number of subjects: 5681
Study 34524044 — intervention group
Group type: COMPARATOR
Intervention: Consult model
Number of subjects: 5681
Study 32027931 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial logo sticker on questionnaire envelopes
Number of subjects: 1877
Study 32027931 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretically informed letter sent with the questionnaire
Number of subjects: 1877
Study 32027931 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretically informed newsletter sent prior to the questionnaire
Number of subjects: 1877
Study 32027931 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication of theoretically informed letter
Number of subjects: 1877
Study 32027931 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled results from theoretically informed letter
Number of subjects: 1877
Study 35789389 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 152
Study 35789389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 32406384 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at ST-36 (Zusanli), needles retained for 30 minutes
Number of subjects: 60
Study 32406384 — intervention group
Group type: COMPARATOR
Intervention: Placebo needling at a control point, needles retained for 30 minutes
Number of subjects: 60
Study 32308822 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive Data Videos (PDVs)
Number of subjects: 252
Study 32308822 — intervention group
Group type: COMPARATOR
Intervention: Conventional Data Videos (DVs)
Number of subjects: 252
Study 35394365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (20-80 mg/twice a day)
Number of subjects: 171
Study 35394365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 32298445 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance (GLB) intervention
Number of subjects: 134
Study 32298445 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention for 6 months)
Number of subjects: 134
Study 35295605 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Pulses (MPP) 120 mg/day for 3 days
Number of subjects: 72
Study 35295605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 35295605 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Pulses (MPP)
Number of subjects: 72
Study 34951324 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaled response format
Number of subjects: 0
Study 34951324 — intervention group
Group type: COMPARATOR
Intervention: Dichotomous response format
Number of subjects: 0
Study 36148493 — intervention group
Group type: EXPERIMENTAL
Intervention: HAIC combined with TKIs and anti-PD-1 immunotherapy (HTP group)
Number of subjects: 58
Study 36148493 — intervention group
Group type: COMPARATOR
Intervention: TACE combined with TKIs and anti-PD-1 immunotherapy (TTP group)
Number of subjects: 58
Study 32907283 — intervention group
Group type: EXPERIMENTAL
Intervention: ACYW135 group meningococcal conjugate vaccine
Number of subjects: 720
Study 33476986 — intervention group
Group type: EXPERIMENTAL
Intervention: Edematous CST at 72 hours (FA = 0.37 ± 0.03)
Number of subjects: 27
Study 33476986 — intervention group
Group type: EXPERIMENTAL
Intervention: Edematous CST at day 7 (FA = 0.35 ± 0.08)
Number of subjects: 27
Study 33476986 — intervention group
Group type: EXPERIMENTAL
Intervention: FA at 72 hours (ρ = −0.22, p = 0.420)
Number of subjects: 27
Study 33476986 — intervention group
Group type: EXPERIMENTAL
Intervention: FA at day 7 (ρ = −0.14, p = 0.624)
Number of subjects: 27
Study 36211695 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-created occupational health intervention focusing on duties clarification and structured roundmaking.
Number of subjects: 0
Study 36211695 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched to intervention group).
Number of subjects: 0
Study 34429517 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin depletion (tryptophan depletion)
Number of subjects: 97
Study 33250338 — intervention group
Group type: EXPERIMENTAL
Intervention: Open administration of antidepressant medication for 8 weeks
Number of subjects: 108
Study 33250338 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled (Hidden) administration of antidepressant medication for 8 weeks
Number of subjects: 108
Study 32150108 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval (HII) exercise
Number of subjects: 47
Study 32150108 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous (MIC) exercise
Number of subjects: 47
Study 32150108 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise intervention)
Number of subjects: 47
Study 35689239 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX01 (1000 mg intravenously on days 1 and 15, followed by 1000 mg on weeks 24 and 26)
Number of subjects: 275
Study 35689239 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously on days 1 and 15, followed by placebo on weeks 24 and 26)
Number of subjects: 275
Study 35689239 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX01
Number of subjects: 275
Study 35689239 — intervention group
Group type: COMPARATOR
Intervention: HLX01 and Placebo
Number of subjects: 275
Study 34933984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (monthly review of medications, patient education, medication adjustment advice)
Number of subjects: 636
Study 36203568 — intervention group
Group type: EXPERIMENTAL
Intervention: 1790GAHB vaccine (1.5/25 µg)
Number of subjects: 0
Study 36203568 — intervention group
Group type: EXPERIMENTAL
Intervention: 1790GAHB vaccine (6/100 µg)
Number of subjects: 0
Study 36203568 — intervention group
Group type: COMPARATOR
Intervention: Control group (active comparator vaccines)
Number of subjects: 0
Study 34523367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 36
Study 34523367 — intervention group
Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 36
Study 36031115 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose (HD) stimulation
Number of subjects: 12
Study 36031115 — intervention group
Group type: COMPARATOR
Intervention: Shuffle programming (algorithmic adaptive conventional stimulation)
Number of subjects: 12
Study 32969946 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna (1.0 g)
Number of subjects: 90
Study 32969946 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium Oxide (1.5 g)
Number of subjects: 90
Study 32969946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32899289 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR) with 4 h time-in-bed (TIB) per night for 10 nights
Number of subjects: 35
Study 32899289 — intervention group
Group type: COMPARATOR
Intervention: Control group with 10 h time-in-bed (TIB) on all nights
Number of subjects: 35
Study 34303000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Enrichment Program (CEP) - 12-week, 24-session multimodal group cognitive rehabilitation intervention
Number of subjects: 37
Study 34303000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Enrichment Program (CEP)
Number of subjects: 37
Study 34303000 — intervention group
Group type: COMPARATOR
Intervention: Active control group (individual holistic rehabilitation as usual care)
Number of subjects: 37
Study 33033035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral remote ischaemic preconditioning (3×5 min cycles)
Number of subjects: 120
Study 33033035 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 120
Study 35420979 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Therapeutic (DT) with reduced counseling
Number of subjects: 399
Study 35420979 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 399
Study 34597330 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 23
Study 34597330 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive High Circuit-Resistance Training (CRT)
Number of subjects: 23
Study 34597330 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 23
Study 32543122 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day consent
Number of subjects: 0
Study 32543122 — intervention group
Group type: COMPARATOR
Intervention: Delayed consent
Number of subjects: 0
Study 33186058 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot drama intervention (watching six dramas with social robots demonstrating RJA behaviours)
Number of subjects: 18
Study 33186058 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot drama intervention
Number of subjects: 18
Study 32416645 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and change in gamma-glutamyl transferase (GGT) at 52 weeks
Number of subjects: 146
Study 32416645 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and change in alanine aminotransferase (ALT) at 52 weeks
Number of subjects: 146
Study 32416645 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional clinical parameters added to models
Number of subjects: 146
Study 32991337 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined care (patient-centered care, increased appointment spacing, improved clinic access, reminders, and tracking)
Number of subjects: 6190
Study 32991337 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined care
Number of subjects: 6190
Study 34711062 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SNT
Number of subjects: 29
Study 34711062 — intervention group
Group type: COMPARATOR
Intervention: Sham SNT
Number of subjects: 29
Study 33979369 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise program (N = 14), three to five times per week for eight weeks
Number of subjects: 27
Study 33979369 — intervention group
Group type: COMPARATOR
Intervention: No prescription for the control group (N = 13)
Number of subjects: 27
Study 32513116 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational session delivered via telephone by a medical peer and feedback from a medical specialist about the cases (expert decisional support) before or after completing a post-test audit.
Number of subjects: 590